Tafasitamab vs Zugocabtagene geleucel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Diffuse Large B-Cell Lymphoma

Shared mechanism: CD19 · full Diffuse Large B-Cell Lymphoma pipeline

Tafasitamab

Marketed by Incyte and partners

Approved in Diffuse Large B-Cell Lymphomamonoclonal antibody
Weak signal

NCT02399085 · Phase 2 · completed

The study was open-label and treated participants in a single group without randomization or a comparator. Its primary endpoint was an objective tumor response measure, with 46 of 80 treated with both drugs achieving a complete or partial response, but the uncontrolled design limits how confidently this result can be attributed to tafasitamab.

Next expected readout: January 2027 · NCT04978584 (registry estimate)

Reported efficacy

Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants (not_applicable)

Result source: NCT02399085

Zugocabtagene geleucel

Developed by CRISPR Therapeutics

CAR-T
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Diffuse Large B-Cell Lymphoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Zugocabtagene geleucel: no structured comparison results are available for Diffuse Large B-Cell Lymphoma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Tafasitamab
Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants NCT02399085 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Follicular Lymphoma

Shared mechanism: CD19 · full Follicular Lymphoma pipeline

Tafasitamab

Marketed by Incyte and partners

Approved in Follicular Lymphomamonoclonal antibody
Reliable signal

NCT04680052 · Phase 3 · active, not recruiting

The trial was randomized, double-blind and placebo-controlled in 654 patients, with progression-free survival as a hard cancer endpoint. In the follicular lymphoma population (548 patients) the tafasitamab arm had a significantly lower risk of progression or death than the placebo arm. The primary endpoint was clearly met.

Next expected readout: December 2027 · NCT07225439 (registry estimate)

No aligned efficacy figure on record for this race.

Zugocabtagene geleucel

Developed by CRISPR Therapeutics

Phase 1/2 in Follicular LymphomaCAR-T
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2030 · NCT05643742 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Follicular Lymphoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Tafasitamab: registry results are on file for Follicular Lymphoma, but their comparison mappings are not yet available.

Zugocabtagene geleucel: no structured comparison results are available for Follicular Lymphoma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tafasitamab's landscape · Zugocabtagene geleucel's landscape